• Facebook Social Icon
  • Twitter Social Icon
  • Instagram Social Icon

Sickle Cell Disease / Sickle Cell Anaemia Clinical Trial


Clinics: Manchester EPU

Therapy Area: Haematology

Gender and Age: Male and Female aged 18 - 60


Sickle cell disease (SCD) or Sickle cell anaemia (SCA) is a genetic blood disorder that occurs when someone has abnormal haemoglobin on their red blood cell called Haemoglobin S (normal haemoglobin type is A). Sickle cell disease changes the shape of a person's red blood cells. They are normally round and concave but SCD changes them to become long and stiff, forming the shape of a sickle. These sickle-shaped blood cells don't flow through veins and arteries easily which leads to them clumping up and clogging the blood vessels. In turn, blood and oxygen can't get through, and parts of the body (like the heart, lungs, and kidneys) can't work the way they should. The blockage also causes pain or crises.

The purpose of this study is to learn more about how a potential new drug for treating SCD symptoms affects the body and how the body processes it.


This trial will run at our Manchester EPU clinic and will last approximately 54 days in total with 7 outpatient visits and 1 x 2-night residential stay. 


Up to £940 plus travel expenses


Key Inclusion Criteria

  • Age of between 18 and 60 years old

  • Diagnosis of sickle cell disease

  • No SCD crises in past 30 days before administration of the study drug.

Key Exclusion Criteria

  • History of stroke

  • Weighing over 110kg or less than 50 kg

Other eligibility criteria will apply. Please contact 0800 633 5507 for more information.

Please click the button below at the bottom of the screen to refer yourself or a friend for this study. Thank you.

Any other information

Eligible patients will receive a comprehensive health screen and study participation will be in collaboration with the patient’s treating physician.